医学
他克莫司
皮密莫司
钙调神经磷酸酶
特应性皮炎
皮肤病科
临床试验
生活质量(医疗保健)
不利影响
外科
药理学
内科学
移植
护理部
作者
Alan B. Fleischer,Mark Boguniewicz
出处
期刊:PubMed
日期:2010-05-01
卷期号:9 (5): 488-98
被引量:7
摘要
Persistent pruritus, or itch, is one of the earliest symptoms of atopic dermatitis (AD). When pruritus is untreated, the incessant scratching response by the patient can increase the inflammatory response, resulting in aggravation of disease symptoms and severity, increasing flares and worsening patient quality of life. Therefore, it is essential that pruritus be treated effectively, rapidly and safely for optimal management of AD. In this article, the authors review clinical trials using tacrolimus ointment, a topical calcineurin inhibitor, to treat adult and pediatric patients with AD over a wide range of disease severity focusing on its efficacy in rapidly reducing pruritus. Furthermore, the authors evaluate trials in which tacrolimus ointment was directly compared with topical corticosteroids, the mainstay of AD treatment, and pimecrolimus cream, another topical calcineurin inhibitor, as well as long-term safety trials in which patients applied tacrolimus ointment for extended periods.
科研通智能强力驱动
Strongly Powered by AbleSci AI